• All News
• Consumer
• Pro
• New Drugs
• Pipeline
• Clinical Trials
• FDA Alerts

Simple Hysterectomy Not Inferior for Pelvic Recurrence in Cervical Cancer

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 29, 2024.

By Elana Gotkine HealthDay Reporter

THURSDAY, Feb. 29, 2024 -- For patients with low-risk cervical cancer, simple hysterectomy is not inferior to radical hysterectomy with respect to incidence of pelvic recurrence at three years, according to a study published in the Feb. 29 issue of the New England Journal of Medicine.

Marie Plante, M.D., from Centre Hospitalier Universitaire de Québec in Canada, and colleagues conducted a multicenter noninferiority trial comparing radical hysterectomy to simple hysterectomy including lymph-node assessment in patients with low-risk cervical cancer (350 patients in each group). The prespecified noninferiority margin was 4 percentage points for the between-group difference in pelvic recurrence at three years.

The researchers found that the incidence of pelvic recurrence at three years was 2.17 and 2.52 percent in the radical hysterectomy and simple hysterectomy groups, respectively, with a median follow-up time of 4.5 years (absolute difference, 0.35 percentage points). In a per-protocol analysis, the results were similar. Within four weeks after surgery and beyond four weeks, the incidence of urinary incontinence was lower in the simple versus the radical hysterectomy group (2.4 versus 5.5 percent and 4.7 versus 11.0 percent, respectively). The simple hysterectomy group also had a lower incidence of urinary retention within and beyond four weeks after surgery (0.6 versus 11 percent and 0.6 versus 9.9 percent, respectively).

"Among patients with low-risk cervical cancer, simple hysterectomy was noninferior to radical hysterectomy with respect to pelvic recurrence at three years and was associated with fewer urologic complications," the authors write.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted February 2024

More news resources

• FDA Medwatch Drug Alerts
• Daily MedNews
• News for Health Professionals
• New Drug Approvals
• New Drug Applications
• Drug Shortages
• Clinical Trial Results
• Generic Drug Approvals

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.